TRPH-222

N/A

Report date: 2024/02/05 13:50:26

Base Information

Drug NameTRPH-222
Drug Alias NameCD22-4APTRPH-222CAT-02-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > 4AP linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCatalent Inc
China Registration ClassN/A

Develop Information

Active CompaniesTriphase Research And Development Iii Corp
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A